Ionis Pharmaceuticals
IONS · NASDAQ
$45.40+$1.02 (+2.30%)TodayMarket closed ·
Prev close $44.38
EPS: actual vs estimate
Beat the estimate in 7 of the last 8 quarters, by 64.7% on average
Next report: , before the market opens
- Quarter
- Q3 FY26
- EPS estimate
- -$0.97
- Revenue estimate
- $185.73M
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$1.09 | -$0.69 | +36.7% |
| Q1 FY26 | -$0.9283 | -$0.56 | +39.7% |
| Q4 FY25 | -$1.35 | -$1.41 | −4.6% |
| Q3 FY25 | -$1.26 | -$0.80 | +36.4% |
| Q2 FY25 | -$0.4387 | $0.70 | +259.6% |
| Q1 FY25 | -$1.14 | -$0.93 | +18.4% |
| Q4 FY24 | -$1.15 | -$0.66 | +42.4% |
| Q3 FY24 | -$1.18 | -$0.95 | +19.5% |
Earnings calls
- Morgan Stanley 24th Annual Global Healthcare Conference
- Wells Fargo 21st Annual Healthcare Conference
- Special Call - Ionis Pharmaceuticals, Inc.
- IONS - Earnings call Q2 2026
- Special Call - Ionis Pharmaceuticals, Inc.
- Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Special Call - Ionis Pharmaceuticals, Inc.
- RBC Capital Markets Global Healthcare Conference 2026
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.